AMGN · Healthcare

AMGEN INC

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Market Demand TrendsImportance 53 · Surprise 48
  Amgen reported broad demand momentum across its commercial portfolio, with 22 products delivering double-digit sales growth in the second quarter. The six key growth drivers increased 26% year over year and contributed…

News · 2026-08-07

• Guidance and OutlookImportance 69 · Surprise 60
  Amgen raised its full-year 2026 revenue outlook to $38.2 billion-$39.4 billion. Management also raised adjusted EPS guidance to $22.30-$23.50 after strong first-half product performance. The guidance increase followed…
• Revenue Performance and MixImportance 38 · Surprise 40
  Amgen’s second-quarter 2026 revenue increased 10% year over year to $10.05 billion. Six key growth drivers increased 26% year over year and contributed nearly 70% of product sales. Twenty-two products delivered…

News · 2026-08-06

• Competition and Pricing PressureImportance 64 · Surprise 42
  Amgen continues to face biosimilar competition in its legacy bone-health franchises, particularly Prolia and XGEVA. Reports described approximately $7 billion of loss-of-exclusivity headwinds affecting older products.…
• Revenue Performance and MixImportance 38 · Surprise 40
  Amgen’s second-quarter 2026 revenue increased 10% year over year to $10.05 billion. Six key growth drivers increased 26% year over year and contributed nearly 70% of product sales. Twenty-two products delivered…

10-Q · 2026-08-05

• Competition and Pricing PressureImportance 76 · Surprise 56
  Prolia sales declined 32% to $1,122 million in the quarter and 33% to $1,486 million for the six months ended June 30, 2026, driven by lower volume and net selling price. Prolia volume declined 20% quarterly and 19%…
• Capital Expenditures ProgramImportance 71 · Surprise 82
  Amgen’s capital expenditures were $1.2 billion in the six months ended June 30, 2026, compared with $780 million in the prior-year period, primarily for new plants and manufacturing-capacity expansion. Management…
• Operating Income and MarginsImportance 69 · Surprise 64
  Second-quarter 2026 operating income increased 32.3% year over year to $3.514 billion from $2.656 billion, lifting operating margin to approximately 35.0% from 28.9%. Six-month operating income increased 61.2% to…
• Liquidity and Debt PositionImportance 69 · Surprise 50
  Cash and cash equivalents increased to $13.989 billion at June 30, 2026 from $9.129 billion at December 31, 2025. Total debt was $57.304 billion, consisting of $5.445 billion of current debt and $51.859 billion of…
• Drug Pricing Policy ImpactImportance 66 · Surprise 74
  The Inflation Reduction Act (IRA) and expanded use of the 340B Program have negatively affected Amgen and are expected to continue affecting access, pricing, reimbursement and sales. CMS selected ENBREL for Medicare…
• Reimbursement and Payer MixImportance 65 · Surprise 60
  The Inflation Reduction Act selected Otezla for Medicare price setting beginning January 1, 2027. The earlier-than-anticipated selection reduced estimated future U.S. cash flows for Otezla and triggered an impairment…
• IRS Tax DisputesImportance 65 · Surprise 60
  Amgen is contesting IRS notices concerning the allocation of profits between U.S. entities and entities in the U.S. territory of Puerto Rico. The 2010–2012 notices could produce approximately $3.6 billion of additional…
• Operating Cash Flow TrendsImportance 63 · Surprise 64
  Net cash provided by operating activities increased to $6.191 billion in the six months ended June 30, 2026 from $3.671 billion in the prior-year period. The $2.520 billion increase primarily reflected the absence of…
• Market Demand TrendsImportance 58 · Surprise 56
  Global BLINCYTO sales increased primarily through volume growth, including 16% volume growth in the second quarter of 2026 and six-month growth driven by volume. Nplate sales increased 23% globally in the first half,…
• Operating Expense TrendsImportance 57 · Surprise 50
  Total operating expenses decreased 7% to $12.492 billion in the six months ended June 30, 2026, primarily because prior-year expenses included an $800 million Otezla intangible-asset impairment charge. Cost of sales…
• Regulatory Approval MilestonesImportance 57 · Surprise 60
  On April 27, 2026, FDA’s Center for Drug Evaluation and Research proposed withdrawing approval of TAVNEOS in the United States. The proposal followed a March 2026 Drug Safety Communication concerning serious, including…
• Guidance and OutlookImportance 56 · Surprise 42
  For the remainder of 2026, Amgen expects volume growth from certain brands to be partially offset by net selling-price declines. Management identifies potential MFN pricing reforms, tariffs, trade-protection measures,…
• IRS Tax ExaminationsImportance 53 · Surprise 60
  The IRS is examining Amgen’s tax years 2016–2018 and issued substantially similar draft notices of proposed adjustment in April, May and July 2026. The proposed adjustments concern profit allocation between the United…
• Revenue Performance and MixImportance 52 · Surprise 56
  Global Nplate sales increased 23% in the six months ended June 30, 2026, including a $60 million U.S. government order; excluding that order, sales increased 15%, driven by 11% volume growth and higher net selling…
• Income Tax Rate ChangesImportance 45 · Surprise 64
  The effective tax rate increased to 14.2% from 8.7% for the second quarter and to 13.6% from 10.7% for the first six months of 2026. The increases primarily reflected a change in earnings mix, including lower…
• Stock Repurchase ProgramImportance 44 · Surprise 24
  Amgen did not repurchase shares under its stock repurchase program during the six months ended June 30, 2026 or the comparable 2025 period. The company had $6.8 billion of remaining repurchase authorization at June 30,…
• Geographic Market CommentaryImportance 43 · Surprise 32
  Demand growth was broad-based geographically, with second-quarter volume increasing 9% in the U.S. and 8% in ROW. For the first six months, ROW volume growth of 10% exceeded U.S. growth of 9%. Growth in both regions…
• Quarterly Dividend DeclarationImportance 42 · Surprise 14
  Amgen declared quarterly cash dividends of $2.52 per share for the first, second and third quarters of 2026, representing a 6% increase over the comparable prior-year periods. Dividend payments totaled $2.7 billion…
• Trade Policy and TariffsImportance 40 · Surprise 42
  The United States and other countries have proposed or implemented numerous tariffs and trade-protection measures, including potential sector-specific tariffs on pharmaceuticals. In April 2026, the U.S. Administration…
• Product Pipeline ProgressImportance 38 · Surprise 60
  In June 2026, the European Commission granted marketing authorization for IMDYLLTRA as monotherapy for adults with extensive-stage small cell lung cancer. The authorization covers patients requiring systemic therapy…
• Regulatory RiskImportance 37 · Surprise 42
  The OECD issued administrative guidance on January 5, 2026, that, when fully enacted, would exempt U.S. companies from extraterritorial minimum taxes effective January 1, 2026. The United Kingdom, EU member countries…
• Macroeconomic Factors ImpactImportance 10 · Surprise 6
  Amgen cites inflation risk, fluctuating interest rates, financial-system instability, rising healthcare costs and geopolitical conflict as ongoing business challenges. Middle East conflict has increased energy and…

News · 2026-08-05

• Guidance and OutlookImportance 69 · Surprise 60
  Amgen raised its full-year 2026 revenue outlook to $38.2 billion-$39.4 billion. Management also raised adjusted EPS guidance to $22.30-$23.50 after strong first-half product performance. The guidance increase followed…
• Market Demand TrendsImportance 53 · Surprise 48
  Amgen reported broad demand momentum across its commercial portfolio, with 22 products delivering double-digit sales growth in the second quarter. The six key growth drivers increased 26% year over year and contributed…
• Revenue Performance and MixImportance 38 · Surprise 40
  Amgen’s second-quarter 2026 revenue increased 10% year over year to $10.05 billion. Six key growth drivers increased 26% year over year and contributed nearly 70% of product sales. Twenty-two products delivered…
• Product Pipeline ProgressImportance 28 · Surprise 42
  Amgen is continuing late-stage development of MariTide, its investigational obesity treatment, including the Phase 3 MARITIME-1-EXTENSION study evaluating long-term weight-loss maintenance and tolerability. The company…

8-K · 2026-08-04

• Capital Expenditure OutlookImportance 75 · Surprise 64
  Amgen reported capital expenditures of $1.225 billion for the six months ended June 30, 2026, compared with $780 million in the prior-year period, an increase of approximately 57%. Second-quarter capital expenditures…
• Free Cash Flow and LiquidityImportance 69 · Surprise 64
  Second-quarter free cash flow increased to $3.5 billion from $1.9 billion, reflecting the final $2025 repatriation tax payment and current-period business performance, partially offset by working-capital timing.…
• Capital Return ProgramImportance 69 · Surprise 50
  Amgen declared a second-quarter 2026 dividend of $2.52 per share, paid June 5, 2026, representing a 6% increase from the same period in 2025. Dividends paid increased to $1.4 billion from $1.3 billion in the prior-year…
• Guidance and OutlookImportance 69 · Surprise 60
  For the year ending December 31, 2026, Amgen reaffirmed GAAP diluted EPS guidance of $15.80 to $17.08 and non-GAAP diluted EPS guidance of $22.30 to $23.50. The non-GAAP range includes primarily acquisition-related…
• Operating Cash Flow TrendsImportance 69 · Surprise 64
  Net cash provided by operating activities increased to $4.002 billion in the second quarter of 2026 from $2.280 billion in the second quarter of 2025. Six-month operating cash flow rose to $6.191 billion from $3.671…
• Capital Expenditures and Free Cash FlowImportance 69 · Surprise 64
  Second-quarter 2026 capital expenditures were $513 million, up from $369 million in the second quarter of 2025. Six-month capital expenditures increased to $1.225 billion from $780 million in the prior-year period.…
• Medicare Drug Price SettingImportance 68 · Surprise 84
  U.S. Medicare Part D price setting under the Inflation Reduction Act became effective for Enbrel on January 1, 2026. Amgen reported that Enbrel’s second-quarter sales declined 4% year over year to $580 million, with…
• Operating Income and MarginsImportance 64 · Surprise 56
  GAAP operating income increased from $2.656 billion to $3.514 billion, and GAAP operating margin rose 6.5 percentage points to 36.8% of product sales. Non-GAAP operating income increased from $4.293 billion to $4.612…
• Competition and Pricing PressureImportance 59 · Surprise 48
  Multiple global biosimilars pressured denosumab products, with Prolia volume down 20% and net selling price down 12%, while XGEVA volume fell 22% and net selling price fell 8%. Enbrel net selling price declined 22%,…
• Income Tax Rate ChangesImportance 57 · Surprise 64
  GAAP income tax expense increased to $393 million from $136 million, while the GAAP tax rate rose 5.5 percentage points to 14.2%. The GAAP tax-rate increase was primarily driven by a change in earnings mix, including…
• Gross Margin DriversImportance 49 · Surprise 32
  GAAP cost of sales decreased 7% year over year to $2.811 billion, reducing cost of sales to 29.5% of product sales from 34.3%. The 4.8-percentage-point GAAP improvement was driven by lower amortization expense from…
• Revenue Performance and MixImportance 47 · Surprise 22
  Second-quarter 2026 total revenue increased 10% year over year to $10.1 billion, while product sales rose 9% to $9.537 billion, driven by volume growth. The six key growth drivers grew 26% year over year and generated…
• Regulatory RiskImportance 47 · Surprise 60
  Amgen continues discussions with the U.S. Food and Drug Administration regarding the Center for Drug Evaluation and Research’s request to voluntarily withdraw TAVNEOS from the U.S. market. The company requested an FDA…
• FDA Clinical HoldsImportance 44 · Surprise 60
  The FDA placed a partial clinical hold on two potentially registration-enabling subcutaneous blinatumomab studies in adults, adolescents, and pediatric patients with relapsed or refractory B-cell precursor acute…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  The European Commission approved IMDYLLTRA as monotherapy for adults with extensive-stage small-cell lung cancer after progression on or after first-line platinum-based chemotherapy. China’s NMPA granted full approval…
• Operating Expense TrendsImportance 37 · Surprise 6
  GAAP total operating expenses were essentially flat at $6.540 billion versus $6.523 billion in the prior-year quarter, despite revenue growth. GAAP R&D expense increased 7% to $1.868 billion, driven by higher…
• Geographic Market CommentaryImportance 37 · Surprise 6
  U.S. product sales were $6.990 billion versus $2.547 billion in the rest of world, representing roughly 73% and 27% of total product sales, respectively. Several growth products were predominantly U.S.-driven,…
• Product Pipeline ProgressImportance 31 · Surprise 42
  Amgen continued Phase 3 development of MariTide across chronic weight management, cardiovascular outcomes, heart failure, obstructive sleep apnea, and switching from tirzepatide or semaglutide, with three additional…
• Supply Chain ConstraintsImportance 31 · Surprise 42
  MariTide is being advanced through multiple Phase 3 studies in chronic weight management, cardiovascular outcomes, heart failure, obstructive sleep apnea, switching from tirzepatide or semaglutide, and long-term…

News · 2026-08-04

• Guidance and OutlookImportance 69 · Surprise 60
  Amgen raised its full-year 2026 revenue outlook to $38.2 billion-$39.4 billion. Management also raised adjusted EPS guidance to $22.30-$23.50 after strong first-half product performance. The guidance increase followed…
• Competition and Pricing PressureImportance 64 · Surprise 42
  Amgen continues to face biosimilar competition in its legacy bone-health franchises, particularly Prolia and XGEVA. Reports described approximately $7 billion of loss-of-exclusivity headwinds affecting older products.…
• Market Demand TrendsImportance 53 · Surprise 48
  Amgen reported broad demand momentum across its commercial portfolio, with 22 products delivering double-digit sales growth in the second quarter. The six key growth drivers increased 26% year over year and contributed…
• Revenue Performance and MixImportance 38 · Surprise 40
  Amgen’s second-quarter 2026 revenue increased 10% year over year to $10.05 billion. Six key growth drivers increased 26% year over year and contributed nearly 70% of product sales. Twenty-two products delivered…
• Cloud Data BreachImportance 37 · Surprise 42
  In July 2026, Amgen reported unauthorized access to third-party-hosted cloud storage systems. The incident involved exfiltration of proprietary data and patient protected health information, and Amgen notified the SEC…
• Free Cash FlowImportance 34 · Surprise 24
  Amgen generated $3.5 billion of free cash flow in the second quarter of 2026. Free cash flow increased significantly from the prior-year period, supporting the company’s raised full-year financial outlook. The $3.5…
• Litigation and Legal RiskImportance 31 · Surprise 42
  Edelson Lechtzin LLP launched a class-action investigation concerning the July 2026 Amgen cloud breach and alleged exposure of patient health information. The investigation relates to unauthorized activity in cloud…
• Product Pipeline ProgressImportance 28 · Surprise 42
  Amgen is continuing late-stage development of MariTide, its investigational obesity treatment, including the Phase 3 MARITIME-1-EXTENSION study evaluating long-term weight-loss maintenance and tolerability. The company…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Amgen declared a quarterly dividend of $2.52 per share in August 2026. The dividend was announced alongside second-quarter revenue of $10.05 billion and adjusted EPS of $6.29. The quarterly payment implies an…